Emd Serono Inc Drug Patent Portfolio

Emd Serono Inc owns 4 orange book drugs protected by 18 US patents Given below is the list of Emd Serono Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10849919 Cladribine regimen for treating progressive forms of multiple sclerosis 23 Nov, 2038
Active
US8580781 Pyridazinone derivatives 19 Mar, 2030
Active
US8329692 Pyrimidinyl pyridazinone derivatives 30 Oct, 2029
Active
US8927540 Pyridazinone derivatives 21 Jul, 2028
Active
US8658643 Pyrimidinyl pyridazinone derivatives 04 Jul, 2028
Active
US9062029 Pyrimidinyl pyridazinone derivatives 04 Jul, 2028
Active
US9403799 Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase 04 Jul, 2028
Active
US8921357 Pyridazinone derivatives 30 May, 2028
Active
US9284300 Pyridazinone derivatives 29 Apr, 2028
Active
US7713947 Cladribine regimen for treating multiple sclerosis 16 Oct, 2026
Active
US8377903 Cladribine regimen for treating multiple sclerosis 31 May, 2026
Active
US7888328 Oral formulations of cladribine 11 Apr, 2024 Expired
US8785415 Oral formulations of cladribine 11 Apr, 2024 Expired
US6319192 Method for the treatment of fertility disorders 23 Apr, 2019 Expired
US6475521 Biphasic controlled release delivery system for high solubility pharmaceuticals and method 19 Mar, 2018 Expired
US6660300 Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method 19 Mar, 2018 Expired
US6863891 Oligopeptide lyophilisate, their preparation and use 22 Feb, 2014 Expired
US7605121 Oligopeptide lyophilisate, their preparation and use 22 Feb, 2014 Expired


Given below is the list of recent legal activities going on the following drug patents of Emd Serono Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329692
Payment of Maintenance Fee, 4th Year, Large Entity 15 May, 2024 US10849919
Payment of Maintenance Fee, 8th Year, Large Entity 17 Jan, 2024 US9403799
Request for Trial Granted 20 Dec, 2023 US8377903
Mail-Petition Decision - Denied 20 Dec, 2023 US7713947
Request for Trial Granted 20 Dec, 2023 US7713947
Petition Entered 19 Dec, 2023 US7713947
Petition Decision - Denied 19 Dec, 2023 US7713947
Request for Trial Granted 22 Sep, 2023 US8377903
Request for Trial Granted 22 Sep, 2023 US7713947
Payment of Maintenance Fee, 8th Year, Large Entity 30 Aug, 2023 US9284300
Termination or Final Written Decision 16 Aug, 2023 US10849919
Electronic Review 10 May, 2023 US8377903
Electronic Review 05 May, 2023 US8377903
Change in Power of Attorney (May Include Associate POA) 13 Apr, 2023 US8377903


Emd Serono Inc's Drug Patent Litigations

Emd Serono Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 10, 2023, against patent number US10849919. The petitioner Hopewell Pharma Ventures, Inc. et al., challenged the validity of this patent, with Ares Trading SA as the respondent. Click below to track the latest information on how companies are challenging Emd Serono Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7713947 October, 2022 Trial Instituted
(20 Dec, 2023)
Merck Serono SA TWi Pharmaceuticals, Inc.
US8377903 October, 2022 Trial Instituted
(20 Dec, 2023)
Merck Serono SA TWi Pharmaceuticals, Inc.
US7713947 January, 2023 Trial Instituted
(22 Sep, 2023)
Merck Serono SA Hopewell Pharma Ventures, Inc. et al.
US8377903 January, 2023 Trial Instituted
(22 Sep, 2023)
Merck Serono SA Hopewell Pharma Ventures, Inc. et al.
US10849919 February, 2023 Terminated-Settled
(16 Aug, 2023)
Ares Trading SA Hopewell Pharma Ventures, Inc. et al.


Emd Serono Inc Drug Patents' Oppositions Filed in EPO

Emd Serono Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 16, 2018, by Generics (Uk) Ltd. This opposition was filed on patent number EP14001970A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14001970A Oct, 2018 Generics (UK) Ltd Granted and Under Opposition


Emd Serono Inc's Family Patents

Emd Serono Inc drugs have patent protection in a total of 42 countries. It's US patent count contributes only to 12.3% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Emd Serono Inc Drug List

Given below is the complete list of Emd Serono Inc's drugs and the patents protecting them.


1. Cetrotide

Cetrotide is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6319192 Method for the treatment of fertility disorders 23 Apr, 2019
(5 years ago)
Expired
US6863891 Oligopeptide lyophilisate, their preparation and use 22 Feb, 2014
(10 years ago)
Expired
US7605121 Oligopeptide lyophilisate, their preparation and use 22 Feb, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cetrotide's drug page


2. Glucophage Xr

Glucophage Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6475521 Biphasic controlled release delivery system for high solubility pharmaceuticals and method 19 Mar, 2018
(6 years ago)
Expired
US6660300 Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method 19 Mar, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucophage Xr's drug page


3. Mavenclad

Mavenclad is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10849919 Cladribine regimen for treating progressive forms of multiple sclerosis 23 Nov, 2038
(14 years from now)
Active
US7713947 Cladribine regimen for treating multiple sclerosis 16 Oct, 2026
(2 years from now)
Active
US8377903 Cladribine regimen for treating multiple sclerosis 31 May, 2026
(1 year, 7 months from now)
Active
US7888328 Oral formulations of cladribine 11 Apr, 2024
(6 months ago)
Expired
US8785415 Oral formulations of cladribine 11 Apr, 2024
(6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavenclad's drug page


4. Tepmetko

Tepmetko is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8580781 Pyridazinone derivatives 19 Mar, 2030
(5 years from now)
Active
US8329692 Pyrimidinyl pyridazinone derivatives 30 Oct, 2029
(5 years from now)
Active
US8927540 Pyridazinone derivatives 21 Jul, 2028
(3 years from now)
Active
US8658643 Pyrimidinyl pyridazinone derivatives 04 Jul, 2028
(3 years from now)
Active
US9062029 Pyrimidinyl pyridazinone derivatives 04 Jul, 2028
(3 years from now)
Active
US9403799 Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase 04 Jul, 2028
(3 years from now)
Active
US8921357 Pyridazinone derivatives 30 May, 2028
(3 years from now)
Active
US9284300 Pyridazinone derivatives 29 Apr, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tepmetko's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Emd Serono Inc News

FDA broadens labeling for Novartis and Roche's popular drug, transforms EMD Serono's treatment for non-small cell lung cancer ...

16 Feb, 2024

See More